Background Cost-value analysis aims to address the limitations of the quality-adjusted life-year (QALY) by incorporating the strength of public concerns for fairness in the allocation of scarce health care resources. To date, the measurement of value has focused on equity weights to reflect societal preferences for the allocation of QALY gains. Another approach is to use a non-QALY-based measure of value, such as an outcome 'equivalent to saving the life of a young person' (a SAVE). Objective This paper assesses the feasibility and validity of using the SAVE as a measure of value for the economic evaluation of health care technologies. Methods A web-based person trade-off (PTO) survey was designed and implemented to estimate equivalent SAVEs for outcome events associated with the progression and treatment of early-stage breast cancer. The estimated equivalent SAVEs were applied to the outputs of an existing decision analytic model for early breast cancer.
Results
The web-based PTO survey was undertaken by 1094 respondents. Validation tests showed that 68 % of eligible responses revealed consistent ordering of responses and 32 % displayed ordinal transitivity, while 37 % of respondents showing consistency and ordinal transitivity approached cardinal transitivity. Using consistent and ordinally transitive responses, the mean incremental cost per SAVE gained was £3.72 million. Conclusion Further research is required to improve the validity of the SAVE, which may include a simpler webbased survey format or a face-to-face format to facilitate more informed responses. A validated method for estimating equivalent SAVEs is unlikely to replace the QALY as the globally preferred measure of outcome, but the SAVE may provide a useful alternative for localized decision makers with relatively small, constrained budgets-for example, in programme budgeting and marginal analysis.
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Introduction
Using the quality-adjusted life-year (QALY) as a measure of outcome, cost-utility analysis reflects societal preferences for different health states. QALYs do not reflect potential societal preferences for improving the health of individuals with lower baseline severity of disease [1] or for incorporating concerns for vertical equity across different population groups within a society [2] . QALYs do implicitly favour technologies for younger and female populations because these groups have greater capacities to gain QALYs, but this aspect is rarely acknowledged or discussed. Empirical studies have demonstrated that the social value of health improvements cannot be adequately represented under the assumption that 'a QALY is a QALY is a QALY' [3, 4] .
Cost-value analysis is intended to reflect a broader set of societal preferences [5] , which may include baseline health status and the characteristics of the treated population. Two broad approaches to cost-value analysis have been proposed. The most common approach estimates weights to reflect the social value of health gains experienced by different population groups, which can be used to adjust estimated QALY gains. Dolan et al. [4] estimated equity weights to represent societal preferences for alternative population groups (e.g. young versus old, severe versus less severe baseline health, cause of ill health). Nord and Johansen [6, 7] estimated functions that estimate 'social values' of QALY gains, which vary according to the baseline utility of the treated population.
The other general approach to cost-value analysis is to use an alternative measure of outcome to the QALY, which facilitates direct assessment of societal preferences for allocation of health gains between different population groups. One such measure-the SAVE-was introduced in 1992. The general SAVE concept involves the use of person trade-off (PTO) survey methods to value alternative health gains relative to a common comparator health gain-initially defined as 'saving the life of a young person' [8] .
In comparison with equity-based adjustment of QALY gains, the potential advantages of the SAVE include direct and intuitive estimation of the joint effects of multiple equity factors (e.g. disease severity, age and cause of ill health), rather than the complex study designs and analytic structures that have been applied to estimate QALY weights for individual factors. The SAVE also removes existing ambiguity around the adjustment of QALY gains by the age of the treated population group, as age can be represented as a characteristic of the treated population and the common comparator (e.g. young persons).
Disadvantages of the SAVE approach may include the time and resources required to estimate relevant sets of SAVE weights for different studies, as well as the likely variability in study design (e.g. in the development of descriptive vignettes). There are also concerns regarding the validity of the PTO method to represent societal preferences-concerns that also apply to most applied approaches to estimating equity-based QALY gain adjustments [9] .
No cost-value analyses using the SAVE as a measure of value have been reported. The aim of this paper is to assess the feasibility and validity of a potential framework for cost-value analysis of health technologies, using the SAVE. A web-based PTO survey was undertaken to estimate the equivalent number of SAVEs associated with avoidance of four clinical events. The resulting equivalent SAVEs were applied to a decision analytic model to estimate the incremental cost per SAVE gained as a cost-value analysis of alternative hormonal therapies for postmenopausal patients with early breast cancer.
A reduced version of a published cohort Markov model was used to test the application of the SAVE as a measure of value [10] . The original set of events represented in the model was reduced to four, on the basis of the severity of the associated quality-of-life and/or survival effects, and the difference in event rates between patients receiving the evaluated interventions (tamoxifen and letrozole). All patients commence the model in a disease-free state, following surgery to remove their primary tumour. They may experience a locoregional recurrence (LRR) or a metastatic recurrence (Mets) of their breast cancer, and they may experience a treatment-related adverse event: a hip fracture (HF) or venous thromboembolism (VTE).
The following sections describe the five stages of the applied SAVE study, including the choice of the health gains, the descriptive vignettes, the valuation instrument, the sampling frame and the methods of analysis.
Choice of Health Gains
In line with the structure of the cost-effectiveness model, SAVEs were estimated for avoidance of four events-LRR, Mets, VTE and HF-all in the context of being a breast cancer survivor. In order to test the feasibility of valuing multiple events with overlapping effects, SAVE weights for avoidance of VTE and Mets, and LRR and Mets, were estimated in combination.
Descriptive Vignettes
Vignettes were developed to describe the survival and quality-of-life effects associated with avoiding each event.
The objective was to achieve a balance between overburdening the respondents with too much information and providing sufficient information for the respondents to provide informed responses.
First, the downstream effect of the events were extracted from the decision analytic model, including the likelihood of LRR progressing to metastatic cancer, and the mortality effects of each event in comparison with patients who remained event free. Second, quality-of-life effects for each event were reviewed from the existing literature, including utility studies [11, 12] and general quality-of-life studies [13] [14] [15] [16] .
The Valuation Instrument
A discussion group of academic colleagues provided feedback on their interpretation of the developed vignettes and the valuation process. First, on the basis of feedback that the original definition of the SAVE as 'saving the life of a young person' was too broad, a revised definition of the SAVE as 'avoidance of the death of one 20-year-old person, who would otherwise live a normal healthy life' was generated. In addition to refining the vignettes for each of the clinical events, the group discussed the upper bound for the number of non-fatal events that would need to be avoided to be equivalent to one SAVE. One hundred was identified as a likely upper bound.
Feedback from the discussion group, and encouraging results from a postal-based PTO survey [17] , encouraged us to use a web-based approach to capture a large sampling frame.
The survey comprised a description of the rationale for the study, an example question to take respondents through the PTO process, four PTO questions comparing clinical events with a SAVE, a fifth PTO question comparing avoidance of LRR and avoidance of HFs (to test for transitivity), and a section for comments.
For each PTO question, respondents were first asked which health gain they would prioritize if only one of each health gain could be funded. Guided by their responses, they were taken through a series of choices (e.g. 1:1 ? 1:100 ? 1:50 ? 1:25 or 1:75) until they reached a predefined point of indifference (1:87, 1:63, 1:37 or 1:12). If still showing a preference at one of these four end points, respondents were asked to specify a value at which they would be indifferent between avoidance of the clinical event(s) and a SAVE. If one SAVE was preferred to avoidance of 100 of the non-fatal events, respondents were asked to specify a value at which they would be indifferent.
The survey went through an extensive process of piloting among academic colleagues, friends and family. Extracts from the final survey are presented in Appendices 1 and 2 in the Electronic Supplementary Material.
The Sampling Frame
Respondents were recruited via the University of Adelaide student mailing list (approximately 20,000 e-mail addresses) and a colour advertisement placed in a widely distributed free local newspaper.
Analysis
The marginal rates of substitution (MRS) between avoidance of each valued event (LRR, HF, LRR ? VTE and HF ? Mets) and a SAVE were estimated. Equivalent numbers of SAVEs for each event were estimated as the reciprocal of the MRS (e.g. 1/MRS LRR/SAVE ). The following tests were then applied to assess the validity of the responses:
• Consistency: avoidance of a double event (e.g. LRR and a VTE) is valued at least as highly as avoidance of the corresponding single events (e.g. LRR alone).
• Ordinal transitivity: if avoidance of LRR is valued more highly than avoidance of HF in the direct comparison of LRR and HF, then the equivalent SAVEs for avoidance of LRR should be higher than the equivalent SAVEs for avoidance of HF (and vice versa).
• Cardinal transitivity: a similar MRS between avoiding LRRs and avoiding HFs should be derived from the direct comparison of LRR and HF, and from the indirect comparison (taking the ratio of the equivalent number of SAVEs for avoidance of both events).
Equivalent SAVEs for avoidance of Mets and VTE events alone were not valued in the survey, because of space constraints and inclusion of the combined events (LRR ? VTE, and HF ? Mets) to test consistency and transitivity. Equivalent SAVEs for these events were fitted, assuming the same multiplicative effect of experiencing multiple events (that the sum of the equivalent SAVEs for the individual events is divided by 1.5).
The numbers of LRR, HF, VTE and Mets events were extracted from the cohort-based state transition model for the two treatment groups. The estimated equivalent SAVEs for each event were applied to the differences in the number of the respective events between the two treatment groups and summed to estimate the total equivalent SAVEs gained.
Lifetime costs were estimated as per normal practice, applying unit costs to time spent in different health states over the course of the model's time horizon of 40 years. The analysis was undertaken from the perspective of the English National Health Service. Table 1 presents the intervention and health state costs (cost year 2005), which are the same as those used as in the original cost-utility analysis [10] , to facilitate a direct comparison between the originally estimated incremental cost per QALY gained and the newly estimated incremental cost per equivalent SAVE gained. Costs were discounted at 5 % per annum, but equivalent SAVEs were not discounted.
Results
There were 1094 responses to the online survey. The average age of the respondents was 24 years (standard deviation 9), 71 % were female and 75 % stated that they had some ''personal or related experience with breast cancer and the health scenarios outlined in this survey''. The following response categories could not be analysed to estimate equivalent SAVE values:
• 3.1 % of respondents entered a response of zero, i.e. they were indifferent between one SAVE and avoiding zero clinical events.
• 21.5 % of respondents stated a preference for avoidance of a single breast cancer event over one SAVE: the survey did not pursue an exact PTO value following this response.
• 11.9 % of respondents had a missing point of indifference after entering a preference for one SAVE over avoidance of 100 breast cancer events. • 12.5 % of respondents had a missing point of indifference after entering a preference for avoidance of 100 breast cancer events over one SAVE. Table 2 reports the results of the consistency and transitivity tests across the responses for which valid SAVE estimates could be derived. The results show a reasonable level of consistency, with 68 % of respondents providing consistent ordering of responses for nested health gains. The ordinal transitivity test showed that 32 % of eligible respondents displayed ordinal transitivity, and 22.5 % of respondents showed consistency and ordinal transitivity.
A ratio of 1 between the directly and indirectly estimated MRS between avoided LRR and HF would indicate that a respondent had perfect cardinal transitivity. Table 2 shows that the mean ratio for respondents with consistency and ordinal transitivity was 40, while the median ratio was 4. Over one third of respondents with consistency and ordinal transitivity (37 %) had a ratio of B2. Table 3 presents the mean and median equivalent number of SAVEs for avoidance of each outcome event. On the basis of the mean response, in respondents with both consistency and ordinal transitivity, avoidance of HF was valued least highly, with 73 avoided events being equivalent to one SAVE. The numbers of avoided LRRs, LRRs ? VTEs and HF ? Mets events equivalent to one SAVE were 58, 42 and 41, respectively. The median responses placed a higher value on all of the health gains, particularly the joint event health gains (the numbers equivalent to one SAVE were 31, 31, 8 and 5 for avoided HF, LRR, LRR ? VTE and HF ? Mets events, respectively). Table 4 shows that patients receiving letrozole experienced fewer Mets, LRRs and VTEs but experienced more HFs than patients receiving tamoxifen. Using the mean SAVE weights, a cohort of 1000 women receiving letrozole rather than tamoxifen would be expected to gain 1.06 SAVEs. Combined with an expected lifetime cost difference of £3.92 million, the incremental cost per SAVE gained would be £3.72 million.
Discussion
This study has presented the first applied economic evaluation using the SAVE as a measure of value. The SAVE is defined as an outcome equivalent to avoidance of the death of one 20-year-old. Compared with the QALY, which reflects preferences between health states, the SAVE reflects preferences relating to alternative health gains (accounting for health status pre-and post-intervention) and the recipients of those health gains (based on relevant characteristics of the recipient group). Equivalent numbers of SAVEs were estimated for avoidance of alternative clinical events, which corresponded to the health states included in a cohort-based state transition model that had previously been developed to inform a cost-utility analysis of alternative hormonal therapies for the treatment of early breast cancer. The online PTO survey attracted a sample of over 1000 respondents, who were mainly university students. This limits the representativeness of the study, but the results still illustrate the potential value of the SAVE as a measure of value and informs the need for investigation of alternative approaches to generating equivalent SAVE weights.
Previous studies have reported a lack of transitivity in responses to PTO questions [17] , and so the PTO survey included strict tests to assess response consistency and transitivity to inform the validity of this application of the SAVE. The response data included a substantial proportion of responses that could not be analysed to generate equivalent SAVEs, because of either ineligible or missing values. Of the 632 valid responses (58 %), 204 (32.3 %) displayed ordinal transitivity and 142 (22.5 %) displayed ordinal transitivity and consistency. Applying the mean and median equivalent SAVEs derived from either of these groups produced very different results. The mean values produced an incremental cost per SAVE gained of over £3.72 million. The estimated median values for the equivalent SAVEs were significantly larger than the mean values, especially for the joint events, and so the intervention would appear more cost effective using the median equivalent SAVE values.
The original QALY-based analysis of tamoxifen and letrozole for patients with early breast cancer estimated an incremental cost per QALY gained of around £20,000. The mean incremental cost per SAVE gained of £3.72 million implies that a SAVE is equivalent to a gain of 224 discounted QALYs in this patient population of postmenopausal women with early breast cancer.
Using a relatively simple hypothetical scenario, Dolan and Tsuchiya [18] reported ordinal and cardinal transitivity after excluding much lower proportions of respondents (between 10 and 41 %, depending on the questionnaire variant). To apply the SAVE to a real-world economic evaluation, the scenarios were required to describe the long-term consequences of each event. The complexity of the scenarios may have contributed to the lower rates of consistency and transitivity.
The reference group, 'saving the life of a 20-year-old', was modified from the reference event specified by Nord [8] ('saving a young life') on the basis of discussion group feedback that the reference should be more specific. The comments section of the survey revealed variation in the interpretation of the reference event. In the absence of specific information on the avoided cause of death, some respondents assigned a cause of death, assuming the 20-year-old whose life was saved was a drug addict, which may explain the high rate of responses that stated a preference for avoidance of a single breast cancer event over a SAVE. Subsequent applications of the SAVE should test the validity of alternative, perhaps more specific reference events-maybe 'curing a terminal disease in a 20-yearold'.
As assessed, the SAVE is unlikely to replace the QALY as the globally preferred measure of outcome for the economic evaluation of health technologies. Even if the methodological issues around consistency and transitivity could be resolved, the time and resources required to undertake separate valuation studies for most economic evaluations would likely be prohibitive. There is also significant potential for variability in the individual components of the SAVE methodology across studies-most importantly, in the specification of the descriptive vignettes (an issue that contributed to decision-maker preferences for multi-attribute utility indices for the estimation of QALYs [19] ).
In addition to concerns around the feasibility and validity of using the SAVE to inform funding decisions, there is also the issue of defining opportunity cost with respect to SAVEs foregone from withholding funding from the best alternative use of resources. While the empirical estimation of opportunity cost with respect to QALYs foregone is at an early stage, decision makers have sought to define threshold values for the incremental cost per QALY gained, against which they can judge the value of new technologies [20] . The lack of empirical estimates of the incremental cost per SAVE gained reduces the objectivity with which decision makers could assess the value of technologies.
However, a validated approach to estimating SAVEs may provide a useful alternative for decision makers with relatively small, constrained budgets-for example, in the context of programme budgeting and marginal analysis (PBMA) [21] . The SAVE may not be relevant for a PBMA within a hospital specialty with no relevant differences in the characteristics of competing patient groups, but for PBMAs involving the allocation of funds across a variety of programmes and population groups, valid estimation of differences in SAVEs between programmes may be a useful approach to incorporating a broad set of societal preferences in the decision-making process. An example of such a PBMA would be around the funding of alternative health promotion and preventative programmes.
In addition to considering an alternative reference event, how might the validity of the SAVE as a measure of value be improved? Face-to-face interviews provide an opportunity to induce respondents ''to carefully consider the various arguments that might be relevant in each exercise and to reconsider initial responses in the light of their implications'' [22] but are necessarily restricted with respect to sample size and selection bias. Face-to-face interviews may also better inform the interpretation of ineligible responses. If missing data or 'zero' responses are reflective of a preference for equity in resource allocation, regardless of capacity to benefit and demographic characteristics, then they may be viewed as valid responses. If such responses are a signal of withdrawal from the resource allocation process, then such responses could reasonably be excluded from the analysis.
Alternatively, Nord [17] has hypothesized that there is a strong random element in individuals' choice of equivalence numbers, which means that PTO needs to be applied in large samples to keep random measurement error at an acceptable level. Since random error does not introduce systematic bias, Nord [17] also suggests that median equivalence numbers may be more reliable measures of value. Web-based survey approaches provide a means of obtaining large and potentially representative samples. However, on the basis of the results reported in this paper, it may be necessary to simplify the survey structure, perhaps eliciting single binary responses from each respondent for each SAVE weight, from which cardinal SAVE weights could be modelled.
Conclusion
The QALY is well established as the preferred measure of outcome in health economic evaluation, despite its welldiscussed limitations [1] . Despite a significant research effort, there is no accepted method for empirical estimation of societal preferences regarding the value of QALY gains to different population groups [23] . The most commonly investigated general approach is estimation of some form of equity weights [4] . The SAVE, as a measure of value, is an intuitive alternative approach, which facilitates measurement of societal preferences with respect to multiple factors (e.g. baseline severity of disease and health inequalities), with no ambiguity around age effects.
As demonstrated by this first application of the SAVE as a measure of outcome in a real-world economic evaluation, significant issues around measurement validity and feasibility remain. However, a valid approach to estimating SAVEs could better inform funding decisions in particular circumstances, such as PBMA exercises in which a constrained budget is being allocated across a limited and heterogeneous set of alternative health technologies and services.
